1
|
Munck HNM, Qvist T, Helleberg M, Kaye PS, Pichon F, Cowan S. At-Risk Groups of Men Who Have Sex With Men Can Be Reached Through Community-Based HIV Testing in Denmark. AIDS Educ Prev 2021; 33:439-449. [PMID: 34369829 DOI: 10.1521/aeap.2021.33.5.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
This study evaluates whether the community-based HIV testing clinic Checkpoint could reach at-risk groups of men who have sex with men (MSM) and link patients to care. A prospective observational study of all Checkpoint visits during 2013-2016 and a retrospective registry study of all MSM diagnosed with HIV in Denmark during the same period were conducted. One percent of the 9,074 tests in Checkpoint were HIV-positive, accounting for 19% of all new HIV diagnoses among MSM in Denmark. Checkpoint testers reported frequent condomless anal sex. Two percent of migrant Checkpoint testers were HIV-positive compared to 1 % among Danish MSM. HIV-positive MSM identified through Checkpoint were significantly younger, more of them were migrant, and a smaller proportion were late testers compared to those testing through the conventional health care system. Checkpoint reaches at-risk populations of MSM and links patients successfully to care.
Collapse
Affiliation(s)
| | - Tavs Qvist
- Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Marie Helleberg
- Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
| | | | | | - Susan Cowan
- Department of Sexually Transmitted Infections and Blood-Borne Viruses, Statens Serum Institut, Copenhagen, Denmark
| |
Collapse
|
2
|
Hoyos J, Maté T, Guerras JM, Donat M, Agustí C, Kuske M, Fuertes R, Chanos S, Pichon F, Sordo L, Pulido J, Belza MJ. Preference towards HIV Self-Testing above Other Testing Options in a Sample of Men Who Have Sex with Men from Five European Countries. Int J Environ Res Public Health 2021; 18:ijerph18094804. [PMID: 33946300 PMCID: PMC8125199 DOI: 10.3390/ijerph18094804] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/16/2021] [Accepted: 04/27/2021] [Indexed: 12/24/2022]
Abstract
We analyzed men who have sex with men (MSM) from Denmark, Germany, Greece, Portugal and Spain to identify who would choose HIV self-testing as their preferred testing method and assessed their preferred setting to acquire a self-testing kit and to confirm a reactive result. In 2016, we recruited an online sample of 3725 HIV-negative MSM. We used Poisson regression to identify factors associated with choosing self-testing as the preferred testing option. For those choosing it as their preferred option, we assessed the preferred settings to acquire a self-testing kit and to confirm a reactive result. Not being open about one's sexual behaviors with men was associated with choosing self-testing as the preferred option, except in Greece; older age in Greece and Spain; reporting condomless anal intercourses (CAI) in Germany and Portugal; reporting one previous test in Greece; between 2 and 5 in Spain and with having been tested ≥ 12 months ago in Germany, Portugal and Spain. The internet (32.8%) was the preferred place to acquire a self-testing kit and primary care (34.0%) for confirmation purposes. Self-testing was highly valued, especially among individuals who were not open about their sexual behaviors with men. In certain countries, it was also associated with older age, CAI and being undertested.
Collapse
Affiliation(s)
- Juan Hoyos
- Departamento de Salud Pública y Materno-Infantil, Universidad Complutense de Madrid, 28040 Madrid, Spain; (J.H.); (L.S.); (J.P.)
| | - Tomás Maté
- Gerencia de Atención Primaria de Valladolid Este, Gerencia Regional de Salud de Castilla y León (SACYL), 47010 Valladolid, Spain
- Correspondence:
| | - Juan-Miguel Guerras
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; (J.-M.G.); (C.A.); (M.-J.B.)
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Marta Donat
- Escuela Nacional de Sanidad, Instituto de Salud Carlos III, 28029 Madrid, Spain;
| | - Cristina Agustí
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; (J.-M.G.); (C.A.); (M.-J.B.)
- Departament de Salut, Centre Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i Sida de Catalunya (CEEISCAT), Generalitat de Catalunya, 08005 Badalona, Spain
| | | | - Ricardo Fuertes
- GAT-Grupo de Ativistas em Tratamentos, 1000-228 Lisboa, Portugal;
| | | | | | - Luis Sordo
- Departamento de Salud Pública y Materno-Infantil, Universidad Complutense de Madrid, 28040 Madrid, Spain; (J.H.); (L.S.); (J.P.)
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; (J.-M.G.); (C.A.); (M.-J.B.)
| | - José Pulido
- Departamento de Salud Pública y Materno-Infantil, Universidad Complutense de Madrid, 28040 Madrid, Spain; (J.H.); (L.S.); (J.P.)
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; (J.-M.G.); (C.A.); (M.-J.B.)
| | - María-José Belza
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; (J.-M.G.); (C.A.); (M.-J.B.)
- Escuela Nacional de Sanidad, Instituto de Salud Carlos III, 28029 Madrid, Spain;
| | | |
Collapse
|
3
|
Itani O, Haddad E, Pitron V, Pichon F, Caumes E. Évaluation de quinze patients recevant un traitement anti-infectieux de plus de 6 mois pour une borréliose de Lyme présumée. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Reyes-Urueña J, Fernàndez-Lopez L, Montoliu A, Conway A, Tavoschi L, Klavs I, Cosmaro L, Eibl I, Dominković Z, Pichon F, Casabona J. Assessing the quality of routine HIV testing data in the community setting 'COBATEST Network'. Int J STD AIDS 2019; 30:999-1008. [PMID: 31335272 DOI: 10.1177/0956462419857572] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The COBATEST Network of Community-Based Voluntary Counselling and STI/HIV Testing (CBVCT) services was created to standardise monitoring and evaluation of CBVCT services across Europe. This study aims to assess the quality of data collected in the network from 2015 to 2016. A survey was completed by 34 COBATEST Network members and an evaluation was performed of data quality based on three dimensions: transcription validity, completeness and consistency. The weakest area that we identified was data management processes. Only 8.8% of services had a written procedure to address data quality errors, 29.4% had procedures in place to resolve discrepancies and 35.3% performed quality control. We found that 41.2% of services utilised the COBATEST data, 11.8% made decisions based on the COBATEST data and 61.8% analysed their data in an independent manner for internal purposes. We conclude that while services have reliable data to support planning and management of services, improvements to quality procedures would ensure data are translated into evidence. This evidence would support further expansion of CBVCT services in the EU/EEA, including the integration of CBVCT-generated data into national surveillance systems.
Collapse
Affiliation(s)
- J Reyes-Urueña
- 1 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Catalonia, Spain.,2 Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
| | - L Fernàndez-Lopez
- 1 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Catalonia, Spain.,2 Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.,3 CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - A Montoliu
- 1 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Catalonia, Spain.,2 Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.,3 CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - A Conway
- 1 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Catalonia, Spain.,2 Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
| | - L Tavoschi
- 4 European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.,5 Department of Translational research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - I Klavs
- 6 National Institute of Public Health, Ljubljana, Slovenia
| | | | - I Eibl
- 8 Aids Hilfe Wien, Austria
| | - Z Dominković
- 9 Iskorak - Sexual and Gender minorities' Rights Centre, Croatia
| | - F Pichon
- 10 The Danish AIDS Foundation, Denmark
| | - J Casabona
- 1 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Catalonia, Spain.,2 Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.,3 CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | | |
Collapse
|
5
|
Hoyos J, Maté T, Indave BI, Agustí C, Chanos S, Pichon F, Kuske M, Cigan B, Fuertes R, Ooms L, Stefanescu R, Cabeza de Vaca C, Arranz B, de la Fuente L, Belza MJ. Knowledge, actual and potential use of HIV self-sampling testing kits among MSM recruited in eight European countries. HIV Med 2019; 19 Suppl 1:27-33. [PMID: 29488699 DOI: 10.1111/hiv.12593] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2017] [Indexed: 11/28/2022]
Abstract
AIM To describe the knowledge as well as current and potential use of self-sampling kits among men who have sex with men (MSM) and to analyse their preferred biological sample and result communication method. METHODS We analyse data of MSM of HIV negative or unknown serostatus from an online survey conducted in eight countries (Belgium, Denmark, Germany, Greece, Portugal, Romania, Slovenia and Spain) between April and December 2016. It was advertised mainly in gay dating websites. We conduct a descriptive analysis of the main characteristics of the participants, and present data on indicators of knowledge, use and potential use of HIV self-sampling as well as their preferences regarding blood or saliva sample and face or non-face-to-face result communication by country of residence. RESULTS A total of 8.226 participants of HIV negative or unknown serostatus were included in the analysis. Overall, 25.5% of participants knew about self-sampling (range: 18.8-47.2%) and 1.1% had used it in the past (range: 0.3-8.9%). Potential use was high, with 66.6% of all participants reporting that they would have already used it if available in the past (range: 62.1-82.1%). Most (78.6%) reported that they would prefer using a blood-based kit, and receiving the result of the test through a non-face-to-face-method (70.8%), even in the case of receiving a reactive result. CONCLUSION The high potential use reported by MSM recruited in eight different European countries suggests that self-sampling kits are a highly acceptable testing methodology that could contribute to the promotion of HIV testing in this population.
Collapse
Affiliation(s)
- J Hoyos
- CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain
| | - T Maté
- Primary Health Care Management of East Valladolid, Valladolid, Spain
| | - B I Indave
- Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain
| | - C Agustí
- CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.,Departament de Salut, Centre Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i Sida de Catalunya (CEEISCAT), Generalitat de Catalunya, Badalona, Spain
| | - S Chanos
- Checkpoint Athens, Athens, Greece
| | - F Pichon
- AIDS Fondet, Copenhaguen, Denmark
| | - M Kuske
- AIDS Hilfe NRW e.V., Berlin, Germany
| | - B Cigan
- Legebitra, Ljubljana, Slovenia
| | - R Fuertes
- GAT-Grupo de Ativistas em Tratamentos, Lisboa, Portugal
| | - L Ooms
- Institute of Tropical Medicine, Antwerp, Belgium
| | - R Stefanescu
- ARAS-Asociatia Romana Anti-SIDA, Bucharest, Romania
| | - C Cabeza de Vaca
- Institute of Health Carlos III, Escuela Nacional de Sanidad, Madrid, Spain
| | - B Arranz
- Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain
| | - L de la Fuente
- CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.,Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain
| | - M J Belza
- CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.,Institute of Health Carlos III, Escuela Nacional de Sanidad, Madrid, Spain
| |
Collapse
|
6
|
|
7
|
Skriada O, Jissendi Tchofo P, Pichon F, Soto Ares G, Pruvo JP. Réévaluation des critères d'interprétation des IRM dans le suivi des gliomes des voies optiques non opérés: variation proportionnelle des composantes charnue et kystique. J Neuroradiol 2007. [DOI: 10.1016/j.neurad.2007.01.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Morland B, Geoerger B, Le Deley MC, Doz F, Pichon F, Frappaz D, Gentet JC, Landman-Parker J, Berthaud P, Vassal G. 246 INVITED Imatinib mesylate in recurrent solid tumours expressing KIT or PDGFR (phase II). EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70251-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Verlooy J, Mosseri V, Bracard S, Tubiana AL, Kalifa C, Pichon F, Frappaz D, Chastagner P, Pagnier A, Bertozzi AI, Gentet JC, Sariban E, Rialland X, Edan C, Bours D, Zerah M, Le Gales C, Alapetite C, Doz F. Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study. Eur J Cancer 2006; 42:3004-14. [PMID: 16956759 DOI: 10.1016/j.ejca.2006.02.026] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2005] [Revised: 02/21/2006] [Accepted: 02/21/2006] [Indexed: 10/24/2022]
Abstract
AIM Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment.
Collapse
Affiliation(s)
- J Verlooy
- Department of Paediatric Oncology, Institut Curie, Service d'Oncologie Pediatrique, 26 rue d'Ulm, 75231 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Vassal G, Geoerger B, Le Deley M, Doz F, Pichon F, Frappaz D, Gentet J, Landman-Parker J, Berthaud P, Morland B. ITCC phase II study of imatinib mesylate in children with solid tumors expressing imatinib-sensitive tyrosine kinase receptors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9003 Background: Imatinib mesylate inhibits selectively specific activations of the platelet-derived growth factor receptor (PDGFR), c-KIT and BCR/ABL tyrosine kinases and is approved for the treatment of chronic myeloid leukemia and gastro-intestinal stromal tumors (GIST). This study evaluated efficacy of imatinib in solid childhood tumors. Methods: Phase II study of imatinib as single agent in children and adolescents with refractory or relapsing solid tumor expressing at least one of the receptors. Patients were to be treated at 340 mg/m2, a dose escalation allowed to 440 mg/m2 after 2 months in case of insignificant improvement. C-KIT, PDGFRα and β expression was determined on archive tissue sections by immunohistochemistry prior to study entry. Gene mutations, pharmacokinetics, pharmacogenetics, and positron emission tomography imaging were assessed. Results: 36 patients, 21 boys, median age 13.7 years (2.2–22.5 y), 12 with brain tumors, 6 fibromatosis, 8 mesenchymal/bone tumors, and 10 other solid tumors, including 1 GIST and 3 chordoma, were treated at 340 mg/m2 daily during a total of 168 months (median 1.9 month/patient, range 0.5–19). 18/36 expressed c-KIT, 10 PDGFRα, 21 PDGRβ; 12 expressed more than one receptor. Ten patients were escalated to 440 mg/m2 due to lack of efficacy. During the 1st month, 17 patients experienced mild toxicity (grade 1 and 2) related to study treatment: gastro-intestinal (n=22), face edema (n=7), asthenia (n=5), tumor induration (n=2), skin toxicity (n=2), thrombocytopenia (n=1). No partial or complete response was observed; 5 patients (2 fibromatosis, 1 GIST, 1 medulloblastoma, 1 pseudo-inflammatory tumor) experiencing durable stable disease have been under treatment for more than 12 months. Interesting tumor stabilization during 10 and 7 months, respectively, was achieved in a brain stem glioma and a renal carcinoma. Glucose uptake on 18FDG PET scan was reduced in a chordoma, although the child progressed and died due to disease. Pharmacokinetic and genetic data are currently evaluated. Conclusions: Imatinib as single agent was well tolerated, but—as used in our study —failed to show measurable anti-tumor effects according the standard criteria in the pediatric malignancies studied. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Vassal
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - B. Geoerger
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - M. Le Deley
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - F. Doz
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - F. Pichon
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - D. Frappaz
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - J. Gentet
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - J. Landman-Parker
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - P. Berthaud
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - B. Morland
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| |
Collapse
|
11
|
Piperno-Neumann S, Bui B, Blay J, Roché H, Pichon F, Peny A, Duclos B, Jimenez M, Perol D, Le Cesne A. A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9521] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9521 Background: Based on the severe toxicity of high dose methotrexate (MTX) in adult patients, an alternative intensive chemotherapy (CT) was designed, associating doxorubicin, cisplatinum and ifosfamide in API-AI regimen. Promising results in 32 patients in a single institution study (Le Cesne ASCO 2004) led to a national multicenter phase II trial coordinated by the FSG of FNCLCC. Methods: Patients with a localized operable osteosarcoma were eligible. API-AI regimen consisted in 2 cycles every 28 days of doxorubicin 60 mg/m2 d1 and d15, cisplatinum 100 mg/m2 d1 and ifosfamide 5g/m2 d2 and d15, with equivalent dose of mesna and lenograstim after each course for 7 days. Good responders ≥95% necrosis (GR) received 2 postoperative API courses, and poor responders <95% necrosis (PR) a salvage regimen of 3 cycles of etoposide 100 mg/m2 d1 to d3 and ifosfamide 4 g/m2 d1 to d3. Results: From March 2001 to January 2004, 43 patients (male/female 28/15) with a median age of 23 years (range 17–50), were included. The median tumor size was 88 mm (13–280). All 43 patients received the preoperative API-AI regimen, with a dose intensity of ≥ 89% of the planned protocol. Toxicity was mainly haematological, with grade 3–4 sepsis, grade 4 neutropenia and thrombocytopenia observed in 12%, 79% and 49% of patients respectively. There was no severe renal and cardiac toxicity. All but 5 patients had a limb sparing surgery performed 77 days (median) after the first cycle (range 56–114 days). Intent to treat analysis showed 16/43 GR (37%). With a median follow-up of 36 months (25–48), the 2 year event-free and overall survival were 74% and 86% respectively. Conclusions: Despite the haematological toxicities, these results compare favorably with other previous induction CT schedules containing MTX in adults. A longer follow-up is required to evaluate the impact of this regimen on overall survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Piperno-Neumann
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - B. Bui
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - J. Blay
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - H. Roché
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - F. Pichon
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - A. Peny
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - B. Duclos
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - M. Jimenez
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - D. Perol
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| | - A. Le Cesne
- Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre C. Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Hôpital Civil, Strasbourg, France; FNCLCC, Paris, France; Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
12
|
Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, Sariban E, Pagnier A, Babin A, Pichon F, Neuenschwander S, Vinchon M, Bours D, Mosseri V, Le Gales C, Ruchoux M, Carrie C, Doz F. Standard-Risk Medulloblastoma Treated by Adjuvant Chemotherapy Followed by Reduced-Dose Craniospinal Radiation Therapy: A French Society of Pediatric Oncology Study. J Clin Oncol 2005; 23:4726-34. [PMID: 16034048 DOI: 10.1200/jco.2005.00.760] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Objective The primary objective of this study was to decrease the late effects of prophylactic radiation without reducing survival in standard-risk childhood medulloblastoma. Patients and Methods Inclusion criteria were as follows: children between the ages of 3 and 18 years with total or subtotal tumor resection, no metastasis, and negative postoperative lumbar puncture CSF cytology. Two courses of eight drugs in 1 day followed by two courses of etoposide plus carboplatin (500 and 800 mg/m2 per course, respectively) were administered after surgery. Radiation therapy had to begin 90 days after surgery. Delivered doses were 55 Gy to the posterior fossa and 25 Gy to the brain and spinal canal. Results Between November 1991 and June 1998, 136 patients (median age, 8 years; median follow-up, 6.5 years) were included. The overall survival rate and 5-year recurrence-free survival rate were 73.8% ± 7.6% and 64.8% ± 8.1%, respectively. Radiologic review showed that 4% of patients were wrongly included. Review of radiotherapy technical files demonstrated a correlation between the presence of a major protocol deviation and treatment failure. The 5-year recurrence-free survival rate of patients included in this study with all optimal quality controls of histology, radiology, and radiotherapy was 71.8% ± 10.5%. In terms of sequelae, 31% of patients required growth hormone replacement therapy and 25% required special schooling. Conclusion Reduced-dose craniospinal radiation therapy can be proposed in standard-risk medulloblastoma provided staging and radiation therapy are performed under optimal conditions.
Collapse
|
13
|
Abstract
Chemotherapy administered during childhood may induce dental abnormalities, such as acquired amelogenesis imperfecta, microdontia, hypodontia and altered root morphology. The magnitude of the defect varies according to the cytotoxic agents, the duration of their use and the stage of tooth development at the time of chemotherapy. Patients who received high-dose chemotherapy before the age of 5 are particularly concerned. The dental supervision of these children is based upon three orthopantomograms: the first one has to be performed before starting chemotherapy and will be used as a reference; the second is done soon after the drug therapy in order to evaluate the first consequences; the third is performed after the eruption of all permanent teeth (age 12-13 in average) in order to determine the dental abnormalities. In case of hypodontia, orthodontic treatment must be considered, but it is necessary to take into account the fact that it may increase the risk of root resorption. Preventive dental care is important for these children. It involves meticulous oral hygiene and frequent dental visits to assess and maintain dental health.
Collapse
Affiliation(s)
- L Nawrocki
- Service d'odontologie, hôpital Jeanne-de-Flandre, Lille, France
| | | | | | | | | | | | | |
Collapse
|
14
|
Cohen R, Navel M, Grunberg J, Boucherat M, Geslin P, Derriennic M, Pichon F, Goehrs JM. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J 1999; 18:403-9. [PMID: 10353511 DOI: 10.1097/00006454-199905000-00002] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To compare the efficacy and the safety of a single intramuscular dose of ceftriaxone, 50 mg/kg, vs. a 10-day course of amoxicillin/clavulanate (amox/clav) therapy, 80 mg/kg/day of amoxicillin: 10 mg/kg/day of clavulanate in three divided doses, in children with acute otitis media (AOM) and to evaluate the changes in nasopharyngeal flora after treatment. METHODS In a prospective, comparative, open randomized, multicenter trial, children were scheduled to return for visits on Days 12 to 14 (main end point) and Days 28 to 42 after the beginning of treatment for AOM. A nasopharyngeal swab for bacterial culture was obtained before the treatment and at Days 12 to 14. RESULTS Between February, 1995, and May, 1996, 513 children with a mean age of 14.2 +/- 6.7 months were enrolled. All the patients were evaluable for the safety and intent-to-treat analyses and 463 for the per protocol efficacy. At Days 12 to 14 clinical success was obtained in 186 of the 235 children (79%) given ceftriaxone and in 188 of the 228 children (82.5%) treated with amox/clav. Among the patients with clinical success on Days 12 to 14, the success was maintained at Days 28 to 42 for 108 of 183 (59%) patients in the ceftriaxone group and 103 of 187 (55%) patients in the amox/clav group. Before the antibiotic treatment the percentages of children carrying Streptococcus pneumoniae (59.1%), Haemophilus influenzae (39.4%), Moraxella catarrhalis (55.7%) and the rate of penicillin-resistant S. pneumoniae (52.2%) were comparable between the 2 groups. At Days 12 to 14 the carriage of S. pneumoniae and M. catarrhalis was significantly different between the patients treated with ceftriaxone, 43.9 and 42.2, respectively, and the patients treated with amox/clav, 17.4 and 11.1%, respectively. Among the children carrying S. pneumoniae at Days 12 to 14, the percentage of penicillin-resistant strains reached 63.4% in the ceftriaxone treatment group and 83.0% in the amox/clav treatment group, (P = 0.02). Adverse events (mainly diarrhea) related to the study medication were reported more frequently (P < 0.0001) in the amox/clav treatment group. CONCLUSIONS In an area with a high rate of penicillin-resistant S. pneumoniae, a single dose of ceftriaxone is as efficient as a 10-day course of amox/clav in the treatment of AOM in young children. There was for the two regimens an increased rate of penicillin-resistant strains among the pneumococci carried, whereas the chance for a child to carry a penicillin resistant S. pneumoniae did not increase after treatment.
Collapse
Affiliation(s)
- R Cohen
- Department of Microbiology and Pediatrics, Intercommunal Hospital of Créteil, France.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Gehanno P, Nguyen L, Barry B, Derriennic M, Pichon F, Goehrs JM, Berche P. Eradication by ceftriaxone of Streptococcus pneumoniae isolates with increased resistance to penicillin in cases of acute otitis media. Antimicrob Agents Chemother 1999; 43:16-20. [PMID: 9869558 PMCID: PMC89013 DOI: 10.1128/aac.43.1.16] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This multicenter, noncomparative, nonrandomized study evaluated the clinical efficacy and safety of ceftriaxone for treating acute otitis media in children following clinical failure of oral antibiotic therapy. Middle-ear fluid samples were collected on day 0 and on day 3, 4, or 5 (day 3 to 5) and were used to test whether ceftriaxone therapy can eradicate Streptococcus pneumoniae isolates with increased resistance to penicillin (MIC >/= 1 mg/liter). At the first visit, on day 0, middle-ear fluid was sampled for bacteriological testing by tympanocentesis or otorrhea pus suction. Patients were administered 50 mg of ceftriaxone/kg of body weight/day, injected intramuscularly once daily, for 3 days. A second sample was collected by tympanocentesis if a pneumococcus isolate for which the MIC of penicillin was >/=1 mg/liter was detected in the day-0 sample and if the middle-ear effusion persisted on day 3 to 5. This second sample was tested for bacterial eradication. One hundred eighty-six children aged 5 months to 5 years, 10 months, with acute otitis media clinical failure were enrolled and treated in this trial. On day 10 to 12, 145 (83.8%) of the 173 patients evaluable for clinical efficacy were clinically cured. Of the 59 patients infected by pneumococci, 36 had isolates for which the MICs of penicillin were >/=1 mg/liter. Of those patients, on day 10 to 12, 32 (88.9%) were clinically cured. Middle-ear fluid samples collected by day 3 to 5 following the onset of treatment with ceftriaxone were sterile for 24 of the 27 (88.9%) patients who were infected as of day 0 by pneumococci for which the MICs of penicillin were >/=1 mg/liter and who were evaluable for bacteriological eradication. On day 10 to 12, 81.4% of S. pneumoniae-infected children and 87.5% of Haemophilus influenzae-infected children were clinically cured. No discontinuation of treatment due to adverse events, particularly due to local reactions at the injection site, were reported. Only 11 adverse events which had doubtful, probable, or possible links with the study treatment were recorded. Both the bacteriologically assessed eradication of pneumococci for which the MICs of penicillin were >/=1 mg/liter and the clinical cure rates demonstrate that ceftriaxone is of value in the management of acute otitis media unresponsive to previous oral antibiotic therapy.
Collapse
Affiliation(s)
- P Gehanno
- Service ORL, Hôpital Bichat, 75018 Paris, France.
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
OBJECTIVES A prospective study in the Paris region to evaluate the clinical and bacteriologic epidemiology of acute otitis media in infants in whom oral antibiotic therapy resulted in clinical failure. METHODS The study included 186 children with a mean age of 17.5 +/- 13.1 months. Two-thirds of them attended a day-care center and 40.8% had a history of recurrent otitis media. The most frequently prescribed prior antibiotics were amoxicillin-clavulanic acid (43% of cases), an oral third generation cephalosporin (22.6%), erythromycin-sulfisoxazole (11.8%) and a first generation cephalosporin (10.2%). The average duration of antibiotic therapy was 6.9 +/- 2.65 days. Specimens for bacterial cultures included 188 samples of middle ear fluid obtained by tympanocentesis and 37 collected from otorrhea fluid. RESULTS One hundred forty-one samples (62.7%) from 126 children yielded 170 bacterial isolates. In 60 children (32.3%) the culture of the ear pus was sterile. Among the 170 bacterial isolates: 67 (39.4%) were Streptococcus pneumoniae (59 patients), of which 77.6% had reduced susceptibility to penicillin (PRSP with penicillin MIC > or = 0.125 mg/l); 61 (35.9%) were Haemophilus influenzae (56 patients) of which 49.2% were beta-lactamase producers; and 8 were Moraxella catarrhalis (8 patients), of which 87.5% were beta-lactamase producers. Thirty-six patients were infected by S. pneumoniae with penicillin MIC > or =1 mg/l. In our study attending day-care center (P = 0.04), temperature >38 degrees C with signs of otalgia (P = 0.02), age <2 years (P = 0.048) and prior antibiotic treatment with erythromycin-sulfisoxazole (P = 0.006) were independently predictive risk factors for patients infected with penicillin-resistant S. pneumoniae. Pneumococcal serogroups 23, 14 and 19 were predominant (25.4, 25.4 and 23.8%, respectively). Penicillin resistance was mainly associated with serogroups 23 and 14. CONCLUSIONS Penicillin-resistant S. pneumoniae isolates are frequently responsible for therapeutic failure in cases of acute otitis media in the Paris region.
Collapse
Affiliation(s)
- P Gehanno
- Department of Otolaryngology, Bichat Hospital, Paris, France
| | | | | | | | | | | |
Collapse
|
17
|
Baranzelli MC, Pichon F, Gourmel B, N'Guyen M, Deligny N, Demaille MC. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. Bull Cancer 1997; 84:141-6. [PMID: 9180836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma. To try to find a possible dose-effect, 10 patients with advanced pretraited relapsed soft tissue sarcoma received 15 g/m2/cycle ifosfamide in continuous infusion during 5 days. A pharmacokinetic study was done for 2 patients. All patients received growth factors, ondansetron and 8 clonazepam. Renal toxicity was evaluated after the first and the second cycle. Twenty two cycles were delivered to patients who have been already treated with ifosfamid (10 patients with 15 g/m2 to 54 g/m2, median 27 g/m2) or cis platinum (2 patients). No major renal or neurologic toxicity was observed; only subclinical modifications of urinary enzymes excretion were found. Two patients had visual hallucinations at the end of a cycle and just in the 2 following days; another presented a neuropathy of inferior limbs. Hematological toxicity was very limited. Pharmacokinetic study did not show induction mechanism at this dosage and with this type of administration. So ifosfamide 3 g/m2 during 5 days is feasible. The few level of complications observed is perhaps linked to the daily dose of 3 g/m2 instead of 4 g/m2 or more used in the other studies.
Collapse
Affiliation(s)
- M C Baranzelli
- Service d'oncologie médicale A, Centre Oscar-Lambrel, France
| | | | | | | | | | | |
Collapse
|
18
|
Baranzelli MC, Lecomte-Houcke M, De Saint Maur P, Herbaux B, Pichon F, Deligny N, Demaille MC. [Atypical decubitus fibroplasia: a recent entity. Apropos of a case of an adolescent girl]. Bull Cancer 1996; 83:81-84. [PMID: 8672861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Atypical decubital fibroplasia (FAD) occurs especially in elderly and physically debilited or immobilized patients. We report one observation which is peculiar due to the patient's young age and its circumstances. The painless mass is situated in hyperpressure areas (shoulder, posterior or lateral chest wall, sacrum). The lesion is situated in the deep subcutis and has ill defined limits; it is characterized by zones of fibrinoid necrosis and fibrosis and a prominent myxoid stroma. The differential diagnoses includes mesenchymatous malignant tumors and non neoplastic fibroblastic proliferations such as proliferative fasciitis and decubitus ulcer. The prominent underlying factor and the initial event contributing to its pathogenesis seems to be ischemia. Although some recurrent cases have been reported, FAD is a benign lesion whose treatment is surgical removal.
Collapse
|
19
|
Pichon F, Chatard JC, Martin A, Cometti G. Electrical stimulation and swimming performance. Med Sci Sports Exerc 1995; 27:1671-6. [PMID: 8614324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The purpose of the study was to examine the influence of a 3-wk period of electrostimulation training on the strength of the latissimus dorsi m. and the swimming performances of 14 competitive swimmers divided into 7 electrostimulated (EG) and 7 control swimmers (CG). The peak torques registered during the flexion-extension of the arm was determined with the help of an isokinetic dynamometer at different velocities (from -60 degrees.s(-1) to 360 degrees.s(-1)). Performances were measured over a 25-m pull buoy and a 50-m freestyle swim. For EG, a significant increase of the peak torques was measured in isometric, eccentric, and concentric conditions (P < 0.5). The swimming times declined significantly (P < 0.01) by 0.19 +/- 0.14 s, for the 25-m pull-buoy, and by 0.38 +/- 0.24 s, for the 50-m freestyle. For CG, no significant difference was found for any of the tests. For the whole group, the variations of the peak torques, measured in eccentric condition (-60 degrees.s(-1)) were related to the variations of the performances (r = 0.77; P < 0.01). These results showed that an electrostimulation program of the latissimus dorsi increased the strength and swimming performances of a group of competitive swimmers.
Collapse
Affiliation(s)
- F Pichon
- Groupe Analyse du Mouvement, UFR STAPS, Université de Bourgogne, Dijon, France
| | | | | | | |
Collapse
|
20
|
Féray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, Reynes M, Maisonneuve P, Bismuth H, Bréchot C. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89:1361-5. [PMID: 1313453 PMCID: PMC442999 DOI: 10.1172/jci115723] [Citation(s) in RCA: 202] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
We have investigated hepatitis C virus (HCV) viremia before and after orthotopic liver transplantation (OLT). 38 patients were examined; 16 were anti-HCV positive and 22 anti-HCV negative pre-OLT in a RIBA-2 test (Ortho Diagnostic Systems Inc., Westwood, MA). HCV-RNA was detected using a modified nested polymerase chain reaction in 14/38 and 10/38 patients before and after OLT, respectively. 7 of these 14 subjects who were HCV-RNA positive before OLT were also positive for serum hepatitis B surface antigen. After OLT, six patients became HCV-RNA positive, likely as a result of transfusions, while four developed a probable recurrence of HCV infection. Infection of the liver graft by the same strain of HCV was indeed demonstrated by sequence analysis of a hypervariable domain (in the envelope region) in two cases. This establishes the possibility of HCV recurrence and shows the usefulness of polymerase chain reaction as the only assay currently capable of identifying HCV infection after OLT.
Collapse
Affiliation(s)
- C Féray
- Hybridotest, Institut Pasteur, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Bismuth A, Arulnaden JL, Samuel D, David MF, Pichon F, Mathieu D, Farahmand H, Farrokhi P, Feray C, Brechot C. [Relapse prevention in liver transplant patients treated for liver involvement due to hepatitis B virus]. Rev Fr Transfus Hemobiol 1992; 35:107-23. [PMID: 1637419 DOI: 10.1016/s1140-4639(05)80111-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Controversy surrounds the indication of liver transplantation in patients with hepatitis B virus infection. The major problem is the very high risk of infection of the graft. Some investigators have suggested that the presence of HBsAg is a contraindication to liver transplantation. Between February 1975 and December 1990, 178 HBs positive patients were transplanted at Paul Brousse Hospital in Professor H. Bismuth's Department, 137 for post hepatitis cirrhosis and 41 for fulminant hepatitis. Since April 1984 we have decided long term immunoprophylactic therapy for all patients with HBs infection. But only from August 1987 our supply of purified anti HBs immunoglobulin has been adequate to treat all our patients according to the following protocol: 10.000 IU during the peroperative phase, 10.000 IU immediately after intervention, 10.000 IU every day for the first 6 days, 10.000 IU when the anti HBs levels were under 150 IU/l. One hundred thirty-nine patients were treated by this method. 110 cleared HBs antigen from their sera and their liver were biologically and histologically free of B virus infection. 29 patients showed reappearance of HBs antigen in their sera and nearly all of them developed objective, histologically confirmed, graft lesions. These lesions are those of classical infection: acute hepatitis, active chronic hepatitis and cirrhosis. So 79% of patients were successfully treated with a follow up of 45 months to 6 months. We also studied the prognostic factors under treatment. The study shows: in the case of fulminant hepatitis, 93% success versus 77% in post hepatitis cirrhosis; in the case of Delta superinfection, 94% success versus 66% with pure B infection; in the absence of HBVDNA in the patient's sera before transplantation, 92% success versus 20% in the presence of HBVDNA. For a better understanding of the overall results, the two following parameters have to be considered: some patients relapsed after stopping their treatment, some other patients, despite repositivation of HBs antigen in their sera showed a paradoxal good evolution. These considerations enable us to obtain HBVDNA positive patients: 10% success, HBVDNA negative patients: Fulminant hepatitis: 100% success B Delta post hepatitis cirrhosis: 100% success B post hepatitis cirrhosis: 92% success.
Collapse
Affiliation(s)
- A Bismuth
- Poste de Transfusion, Hôpital Paul Brousse
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Girard P, Lepretre A, de Truchis P, Landman R, Pichon F, Saimot A, Coulaud J. Traitement de relais de la pneumopathie à Pneumocystis carinii par les aérosols de pentamidine. Med Mal Infect 1992. [DOI: 10.1016/s0399-077x(05)80931-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Pichon F, Lagarde AE. Autoregulation of MeWo metastatic melanoma cell growth: characterization of intracellular (FGF, MGSA) and secreted (PDGF) growth factors. J Cell Physiol 1989; 140:344-58. [PMID: 2745568 DOI: 10.1002/jcp.1041400221] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
MeWo melanoma cells (clone LC1) secrete a potent mitogenic activity susceptible to reinitiate DNA replication in quiescent rodent fibroblasts (CCL39, NRK-49F, NIH-3T3) but not in BHK-21 kidney cells. This activity appears to be closely related to platelet-derived growth factor (PDGF) based on 1) its cationic nature, heat and acid resistance, but sensitivity to reducing agents; 2) its apparent molecular weight (33 kDaltons) as estimated by Biogel filtration, once dissociated from binding proteins by mild acidic treatment; 3) its weak affinity for heparin; and 4) its ability to compete with 125I-PDGF for binding to human and rodent fibroblasts, and to be recognized by anti-PDGF antibodies. Although MeWo cells coexpress the PDGF-A and PDGF-B (c-sis) chain gene transcripts, the secreted product shows reactivity on CCL39 fibroblasts more compatible with the PDGF-BB than with the PDGF-AB isoform. MeWo cell lysates contain activities that bind moderately and strongly to heparin-Sepharose, being eluted with 1.0 and 2.0 M NaCl, respectively. The latter may correspond to basic fibroblast growth factor (basic FGF), consistent with the expression of basic FGF gene mRNAs. The former has not been fully characterized and is probably not the product of the acidic FGF gene. In addition, MeWo cells react positively with the FB2 AH7 antibody, thus indicating that they elaborate material similar to melanoma growth-stimulating activity (MGSA). MeWo cells proliferate in serum-free medium in a cell-density-dependent fashion, both in liquid and semisolid cultures. Their division is modestly enhanced by basic FGF and by human and porcine PDGF but not by the factors that they release. However, the absence of demonstrable 125I-PDGF binding sites on MeWo cells, in conjunction with their lack of sensitivity to suramin growth inhibition, suggests that the secreted PDGF does not act as an autocrine factor. Instead, the autonomous proliferation of MeWo melanoma cells may result from the concerted action of basic FGF and MGSA, which are mostly cell-associated.
Collapse
Affiliation(s)
- F Pichon
- Division of Cancer and Cell Biology, Mount Sinai Hospital Research Institute, Toronto, Ontario, Canada
| | | |
Collapse
|
24
|
Pangon B, Bizet C, Buré A, Pichon F, Philippon A, Regnier B, Gutmann L. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 1989; 159:1005-6. [PMID: 2651531 DOI: 10.1093/infdis/159.5.1005] [Citation(s) in RCA: 112] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
|
25
|
Pichon F, Seuwen K, Pouysségur J, Lagarde AE. Progressive relaxation of Go-arrest controls and altered responsiveness to insulin, EGF and thrombin in CCL39 lung fibroblasts over-expressing myc and ras oncogenes. Oncogene 1988; 3:373-81. [PMID: 3078948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Factor-dependent hamster lung fibroblasts (CCL39) were transfected with plasmid vectors expressing normal Ha-ras, T24 Ha-ras, V-Ki-ras or myc oncogenes placed under the transcriptional control of potent viral or inducible (metallothionein-I) promoters. The rate at which clonal isolates proliferated in monolayer cultures in serum-free medium or in response to progression (insulin, EGF) and competence growth factors (alpha-thrombin) was found to vary according to the level of oncogene expression. Low levels of T24 ras gene did not abrogate Go-arrest controls but rendered CCL39 cells responsive to both insulin and EGF. Moderate levels (3- to 10-fold) of T24 and Ki-ras genes induced autonomous growth in serum-free medium and attenuated the cell responsiveness to all three factors. Growth of highest ras expressors was enhanced by low (less than 100 microM) concentrations of suramin, and was partially or not inhibited at higher concentrations. In contrast, EGF but not insulin, was able to recruit quiescent cells expressing moderate (less than or equal to 5-fold) myc levels. Higher levels conferred growth autonomy as well as hypersensitivity to insulin, EGF and thrombin. Suramin abolished the self-replication of such myc cells, thus suggesting an autocrine mechanism of proliferation. Hence, both myc and ras genes provided CCL39 cells with distinct growth competence functions which enabled these cells to respond overall more efficiently to functionally distinct classes of mitogens, or to sustain a completely autonomous replication, depending on the abundance of their respective products. Negative autoregulatory mechanisms may additionally be set into motion in this system when activated ras oncogenes are excessively expressed.
Collapse
Affiliation(s)
- F Pichon
- Division of Cancer and Cell Biology, Mount Sinai Research Institute, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
26
|
Raffi F, Regnier B, Pichon F, Leport C, Vilde JL. Pseudomonas aeruginosa sepsis presenting as peripheral subcutaneous nodules. Report of 2 cases. Intensive Care Med 1988; 14:434-6. [PMID: 3403778 DOI: 10.1007/bf00262903] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Two patients developed disseminated subcutaneous nodules with febrile illness. In both cases, Pseudomonas aeruginosa was isolated from the lesions; blood cultures yielded the same organism in one case, and were negative in the other. The portal of entry was thought to be a jugular hemodalysis catheter in the first case and a necrotic zoster complicating lymphoma in the second case. Both patients' condition improved with antibiotic therapy and the Pseudomonas nodules resolved without surgical drainage.
Collapse
Affiliation(s)
- F Raffi
- Infectious Diseases Department, Claude Bernard Hospital, Paris, France
| | | | | | | | | |
Collapse
|
27
|
Simon F, Le Bras J, Charmot G, Girard PM, Faucher C, Pichon F, Clair B. Severe chloroquine-resistant falciparum malaria in Gabon with decreased sensitivity to quinine. Trans R Soc Trop Med Hyg 1986; 80:996-7. [PMID: 3299907 DOI: 10.1016/0035-9203(86)90290-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
28
|
Masquelet AC, Carlioz H, Pichon F. [Occult spinal dysrhaphia. Anatomoclinical study and therapeutic indications. Apropos of 20 cases]. Ann Pediatr (Paris) 1984; 31:127-36. [PMID: 6712108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
29
|
Carlioz H, Pichon F, Barthélémy A, Lebard JP, Filipe G. [Progressive bone lengthening using Wagner's technique (author's transl)]. Rev Chir Orthop Reparatrice Appar Mot 1980; 66:473-83. [PMID: 6450998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The authors have reviewed the results of 30 surgical procedures of progressive bone lengthening using the Wagner's technique. In 28 cases, internal fixation was applied at the end of the lengthening period. There were 17 femora and 13 tibae operated on. In 6 cases, lengthening was associated with a correction of the alignment of the femur, and in 2 cases was associated with the treatment of a non-union of the tibia. Complications are described; they were found to be relatively rare.
Collapse
|
30
|
Roy-Camille R, Derlon JM, Saillant G, Poirier J, Pichon F. Experimental spinal cord sections. Arch Orthop Trauma Surg (1978) 1978; 92:113-22. [PMID: 363092 DOI: 10.1007/bf00397946] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
31
|
Pichon F, Carlioz H. [Approaches to the hip in the child. I. Partial approaches (author's transl)]. Nouv Presse Med 1978; 7:1391-4. [PMID: 673673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
It exist multiple approaches to the hip in the child. This first section is devoted to a description of those approaches which offer only limited exposure of the joint. Alongside the medial approach used for joint puncture and the obturator approach, scarcely of any use, three important approaches respecting the integrity of the gluteal muscles may be used: those of Hueter and of Watson-Jones, to the anterior aspect of the neck of the femur and that of Moore, approaching its posterior aspect.
Collapse
|
32
|
Pichon F, Roy-Camille R. [Judet's pedicled graft at the level of the femur neck. Anatomical study and vascular consequences in the femur head]. Rev Chir Orthop Reparatrice Appar Mot 1974; 60:223-31. [PMID: 4278673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|